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Edited by Jesus AvilaAbstract Self-propagation is characteristic property for a prion
conformation. Previous studies revealed that prion protein ex-
pressed in the cytoplasm gained a PrPSc-like conformation.
However, it remains unclear whether the PrPSc-like conforma-
tion has the self-propagating property. We found that PrP par-
tially puriﬁed from yeast cytoplasm formed amyloid ﬁber like
structures, and we found that the PrPSc-like conformation is able
to convert normal PrPC in the brain homogenate to a proteinase
K-resistant conformation. These results suggest that yeast cyto-
plasm expressed recombinant PrPSc-like conformation has the
characteristic self-propagating property of a prion, which may
have implications in the pathogenesis of sporadic and inherited
prion diseases.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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PrPC is a-helical rich, detergent soluble, and sensitive to pro-
tease digestion. During prion disease, a portion of PrP mole-
cules converts to a b-sheet rich, aggregated, and protease
resistant PrPSc conformation [1]. The ‘‘protein-only’’ hypothe-
sis proposes that PrPSc is the infectious agent [1,2]. By virtue of
its unusual self-propagating characteristic, PrPSc converts nor-
mal host PrPC into the PrPSc conformation, and subsequently
leads to neurodegeneration. Compelling experimental evi-
dence, particularly the recent ﬁndings that amyloid ﬁbers made
from recombinant PrP89-230 is able to cause prion disease in
transgenic mice overexpressing PrP89-230 [3] and in vitro
ampliﬁed infectious mammalian prion caused disease in wild-
type mice [4], strongly supports the ‘‘protein-only’’ hypothesis.
The self-propagating property of PrPSc was ﬁrst demon-
strated in the cell free system [5], showing that highly puriﬁed
PrPSc is able to convert puriﬁed normal PrP into an aggregated
and proteinase K (PK) resistant conformation [5]. Recently, a
more sensitive and robust assay, the protein-misfolding cyclicAbbreviations: PrP, prion protein; PMCA, protein misfolding cyclic
ampliﬁcation; PK, proteinase K; ER, endoplasmic reticulum; EM,
electron microscopy
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doi:10.1016/j.febslet.2006.06.074ampliﬁcation (PMCA), was developed [6]. Both the PrPSc con-
formation and prion infectivity were successfully propagated
in vitro using PMCA [4]. The mechanism of PrP conversion
process was dissected with a modiﬁed PMCA assay [7], reveal-
ing that polyanions stimulate PrP conversion [8]. Among all
the polyanions tested, RNA molecules (>0.2 kb in length)
are the most potent stimulators [9]. These results clearly estab-
lished that PrPSc conformation is a prion with the self-propa-
gating characteristic.
In all the in vitro conversion assays, PrPSc from diseased
brains were used as seed to study its propagation. Till now,
no recombinant PrPSc-like conformation has been reported
to successfully seed PrP conversion in vitro. Previous studies
revealed that a recombinant PrPSc-like conformation could
be generated by high-level expression of wild-type PrP in the
yeast cytoplasm [10]. A recent study revealed that a N-terminal
hydrophobic amino acid stretch (amino acid 112–119) is cru-
cial for PrP to gain the PrPSc-like conformation in the yeast
cytoplasm [11]. This study also revealed that the same amino
acid stretch is essential for prion propagation in prion-infected
mammalian cells, while it remains unclear whether yeast cyto-
plasm generated PrPSc-like conformation has the self-propa-
gating property.
We analyzed recombinant PrP expressed in the yeast cyto-
plasm to determine whether it has this unusual property of a
prion. Our results suggest that, besides the biochemical simi-
larities to PrPSc, cytoplasm generated recombinant PrPSc-like
conformation also has the characteristic self-propagating
property as a prion.2. Materials and methods
2.1. Plasmid construction and yeast strain
Yeast expression plasmid mPrP (23-230)-p2UGPD was described
previously [10]. In all experiments described here, a pep4
knockout yeast strain W303 (MATa ade2-1 can1-100 his3-12, 16
leu2-3,112 trp1-1 ura3-1) was used (a kind gift from Susan Lind-
quist’s lab).
2.2. Solubility and PK digestion of yeast expressed PrP
Yeast spheroplast was obtained with Zymolyase 100 T (MP Bio-
chemicals) for 2 or 3 h at 30 C, and lysed in two volumes PBS plus
protease inhibitors (aprotinin, pepstatin and leupeptin) with or with-
out 10% (w/v) Sarkosyl (Sigma). Yeast lysates were pre-cleared with
a 5 min 2000 · g spin. For separation of supernatant and pellet frac-
tions, the yeast lysate was sedimented at 16000 · g for 30 min at
4 C. For PK digestion, pre-cleared yeast lysates were digested with
PK (Merck) at 37 C for 30 min at indicated PK concentrations, and
5 mM phenyl-methyl sulphonyl ﬂuoride (PMSF) was added to termi-
nate PK digestions.blished by Elsevier B.V. All rights reserved.
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microscopy analysis
Transformed yeast cells were collected by centrifugation, and cell
pellet was resuspended in ice-cold PBS and disrupted by FRENCH
Press FA-080-E1 (Thermo Spectronic) according to user’s manual. Ly-
sates were pre-cleared, and the supernatant fraction was collected and
centrifuged again at 16000 · g for 30 min at 4 C. The pellet was resus-
pended in PBS containing 10% (w/v) Sarkosyl. The centrifugation and
resuspension procedures were repeated twice, and the ﬁnal pellet was
resuspended in PBS.2.4. Electron microscopy (EM)
Samples of partially puriﬁed PrP were absorbed to glow discharged
carbon-coated copper grids. After washed twice with deionized water,
samples were negatively stained with 2% uranyl acetate for 30 s and
air-dried. Grids were analyzed using a Hitachi H600A electron micro-
scope.2.5. Preparation of normal brain homogenates for conversion assay
Whole brain was harvested from normal, pathogen free BALB/C
mice or Sprague-Dawley rats. Normal brain was homogenized in
PBS plus protease inhibitors. Crude homogenates were pre-cleared
with a 30 s centrifugation at 1000 · g and aliquots of the supernatant
were stored at 70 C.2.6. In vitro conversion assay
We employed a modiﬁed PMCA assay as previously described [7].
Brieﬂy, 50 ll of 5% or 20% normal brain homogenate was mixed with
50 ll of total yeast lysates. The mixture was incubated for 16 h at 37 C
with continuous shaking at 200 rpm. 20 ll of each conversion mixture
were digested at 37 C with PK with indicated concentrations. The PK
digestion was carried out for 30 (for experiments described in Fig. 5) or
60 min (for experiments described in Figs. 3 and 4). PMSF (5 mM) was
added to terminate PK digestions.2.7. Immunoblot analysis
Following electrophoresis, proteins were transferred to PVDF mem-
brane. The anti-PrP 8H4 monoclonal antibody (a gift kindly provided
by Dr. Man-sun Sy) was used at 1:1000 and a horseradish peroxidase-
labeled anti-mouse IgG secondary antibody (GE Healthcare) was used
as secondary antibody with a dilution at 1:5000. The blot was devel-
oped with the ECL-plus reagent (GE Healthcare).2.8. Preparation of RNA
RNA was extracted with Trizol reagent (Invitrogen) and precipi-
tated with isopropanol, according to manufacturer’s instructions.Fig. 1. Analysis of PrP protein generated in the yeast cytosol. (A)
Total proteins from W303 yeast lysates (Ctl) or transformed yeast
lysates (PrP). (B) Transformed yeast lysates (Total) were extracted with
10% Sarkosyl and subjected to sedimented, and PrP in the supernatant
(Sup) and pellet fractions (Pellet) were detected. (C) Proteins from
transformed yeast lysates were digested with PK at the indicated
concentrations at 37 C for 30 min. The arrow and the asterisk indicate
speciﬁc proteinase-resistant bands. (D) Proteins from mouse brain
homogenate were digested with PK at the indicated concentrations at
37 C for 30 min.3. Results
3.1. Expression and characterization of PrP expressed in yeast
cytoplasm
We expressed PrP in the cytoplasm of yeast in which a ma-
jor vacuolar protease PEP4 was deleted [12]. Immunoblot
analysis revealed that PrP exhibited a molecular mass of
approximately 25 kDa (Fig. 1A), as expected for unglycosy-
lated PrP lacking the glycosylphosphatidylinositol (GPI)-
anchor.
The majority of PrP was insoluble in 10% Sarkosyl and ap-
peared in the pellet fraction (Fig. 1B). Yeast cytoplasm ex-
pressed PrP resists PK digestion with PK concentrations
ranging from 2 to 20 lg/ml. The apparent molecular weights
of PK resistant PrP fragments were around 20 kDa and
15 kDa (Fig. 1C). As a control, the PrPC present in the brain
homogenates was completely removed with PK concentration
as low as 5 lg/ml (Fig. 1D).3.2. Amyloid ﬁbrils spontaneously formed by PrP expressed in
the yeast cytoplasm
Amyloid ﬁbers are ordered aggregates that are generally
associated with self-propagating property [13]. EM analysis
was performed to determine the physical properties of PrP
aggregates. We used a puriﬁcation scheme based on Sarkosyl
extraction and diﬀerential centrifugation to obtain partially
puriﬁed PrP. A variety of amyloid ﬁber like and/or bead-like
structures were observed (Fig. 2A–G). The diameter of the
ﬁbrils varied, generally ranging from 10 nm to around
40 nm. The length of the ﬁbers was also diverse, with some
as long as 800 nm. The predominant protein aggregates were
in a bead-like structure with a diameter around 20 nm
(Fig. 2A–G). Besides these two structures, some irregular
shaped protein aggregates were also observed. Control yeast
lysates were prepared from yeast without PrP expression
using exactly the same puriﬁcation regime. As shown in
Fig. 2, none of the structures described above were observed
in control samples.
Fig. 3. In vitro ampliﬁcation of PrPres. The mixture of 5% (w/v)
normal mouse brain homogenate (MBH) and transformed yeast
lysates (CyPrP) was incubated for 16 h at 37 C. The mixture or MBH
or CyPrP were digested with 5 lg/ml PK at 37 C for 60 min. Equal
loading was veriﬁed by total stain of the blot.
Fig. 2. Electron micrographs show ﬁbrils spontaneously formed by PrP generated in yeast cell system. Puriﬁed PrP (A–G) and analogous fractions
from control yeast lysates (Controls 1 and 2) were negatively stained with uranyl acetate. Bars represent 100 nm.
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PrP in brain homogenates to a PK-resistant conformation
The ability of yeast cytoplasm expressed PrP to form or-
dered aggregates implies that it is able to self-propagate its
PK-resistant conformation. To directly test this possibility,
we followed a modiﬁed PMCA protocol [7]. A signiﬁcant
amount of PK resistant PrP was detected with a molecular
weight around 25 kDa (Fig. 3, lane 4). As controls, same
amounts of mouse brain homogenate or yeast spheroplast ly-
sates were also subjected to the PK digestion respectively.Fig. 4. Speciﬁcity of in vitro ampliﬁcation of PrPres. (A) W303 yeast
lysates (Yeast) or transformed yeast lysates (CyPrP) was mixed with
5% (w/v) normal mouse brain homogenate (MBH), followed by
incubation for 16 h at 37 C. (B) The mixture of 5% (w/v) normal rat
brain homogenate (RBH) and transformed yeast lysates (CyPrP) was
incubated for 16 h at 37 C. The mixture or RBH were digested with
5 lg/ml PK at 37 C for 1 h.
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pletely removed by PK digestion (Fig. 3, lane 2). Some PK
resistant PrP bands were detected in yeast spheroplast lysates
(Fig. 3, lane 3), which may represent the PrPSc-like conforma-
tion generated by cytoplasm PrP. Importantly, the amount of
PK resistant PrP in the yeast lyates was signiﬁcantly lower
than that in the conversion reaction (compare lane 3 and 4
of Fig. 3). Protein stain of the PVDF blot veriﬁed a similar le-
vel of PK digestion, ruling out the possibility that a weaker PK
digestion was responsible for the PrP detection (Fig. 3, protein
stain). The increase of PK resistant PrP fragment after the
incubation (Fig. 3, lanes 2–4) suggests that yeast cytoplasm ex-
pressed PrP can act as a seed to convert normal PrP in the
brain homogenate to a PK-resistant conformation.
To rule out the possibility that the conversion observed here
was due to other components in the yeast lysates, we per-
formed the conversion assay with yeast lysates prepared from
yeast with or without cytoplasm PrP expression. Notably, PrP
conversion was only observed in the presence of lysates pre-
pared from PrP expressing yeast, while no conversion was ob-
served in the reaction with control yeast lysates (Fig. 4A). To
rule out the possibility that only mouse PrP in the brain
homogenate is susceptible to cytoplasm PrP induced conver-
sion, we performed the same experiment with 5% rat brain
homogenates. A similar conversion of PrP to the PK-resistant
conformation was observed (Fig. 4B).
Generally, the PrPSc from diseased brain is highly resistant
to PK digestion. However, the newly converted PK resistantFig. 5. Characteristics of in vitro ampliﬁcation of PrPres. (A) The mixture o
yeast lysates(CyPrP) was incubated for 16 h at 37 C. The mixture or MBH
30 min. (B) Eﬀects of RNase A on in vitro ampliﬁcation of PrPres. The mixtur
lysates was incubated with Rnase A in indicated concentrations. (C) RNase
electrophoresis of total RNA prepared from the mixture of 20% (w/v) normal
Rnase A in indicated concentrations.PrP could only resist 5 lg/ml of PK digestion (Figs. 3 and 4A
and B). One of the possible reasons for this lower level of PK
resistance could due to diﬀerence in the concentrations of
brain homogenate used here. We used 20% mouse brain
homogenate for the conversion reaction. Notably, the newly
converted PK resistant PrP showed a higher resistance to
PK digestion, with ﬁnal PK concentrations at 50 lg/ml and
100 lg/ml (Fig. 5A).
3.4. The conversion seeded by yeast cytoplasm expressed PrP
depends on the presence of RNA molecules
Recent reports revealed that RNA plays an important role in
the in vitro PrP conversion [9]. We included diﬀerent concen-
trations of RNase A (Sigma) in the conversion. Notably, the
amount of PK resistant PrP decreased with increasing concen-
trations of RNase A (Fig. 5B). We performed a control exper-
iment to monitor the amount of RNA subject to RNase A
treatment. Incubation did cause some RNA degradation (com-
pare lanes 1 and 4 in Fig. 5C). However, a signiﬁcant decrease
of the total amount of RNA was only observed when RNase A
was included (lanes 2 and 3 in Fig. 5C).4. Discussion
One of the most important characteristics of a prion is its
ability to self-propagate its conformation [1]. Our results from
the modiﬁed PMCA conversion suggest that cytoplasm ex-f 20% (w/v) normal mouse brain homogenate (MBH) and transformed
or CyPrP were digested with 50 lg/ml or 100 lg/ml PK at 37 C for
e of 20% (w/v) normal mouse brain homogenate and transformed yeast
A did degrade RNA molecules in the brain homogenates. Agarose gel
mouse brain homogenate and transformed yeast lysates incubated with
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homogenate to a PK-resistant conformation. The observation
that cytoplasm expressed PrP is able to form amyloid ﬁber like
structures supports that it has the self-propagating ability as a
prion.
Previous studies and results from this study showed that
PrP could achieve a variety of conformations in the yeast
cytoplasm [10], which were illustrated by the size of PK
resistant PrP ranging from full-length to 20 kDa or
15 kDa. Since the cytoplasmic environment, such as redox
potential and chaperones, diﬀers quite dramatically from
that in the lumenal side, it is not surprising that PrP in
the cytoplasm can achieve a variety of conformations. How-
ever, it is not clear whether all the PK-resistant cytoplasm
PrP conformations have the self-propagating property, or
just one of them has this property. Further studies are re-
quired to develop puriﬁcation schemes to separate diﬀerent
PrP conformations, which will allow us to ﬁnd an answer
to this question.
Another question needs to be further studied is whether
yeast cytoplasm expressed PrP is infectious to animals.
Although this PrP could propagate its conformation, it might
be no infectious to animals. It is possible that it is not the
infectious PrP form in prion diseases, or that an infection-
facilitating factor is missing in the yeast lysates. As men-
tioned above, the existence of such a factor can explain the
observations that the recombinant PrP amyloid ﬁber has a
low infectivity [3] while the prion infectivity generated in
the presence of brain homogenate is high[4]. In addition, a re-
cent report showed that scrapie brain microsome has a much
greater eﬃciency to infect cultured cells than puriﬁed PK
resistant PrP [14] also supports the existence of an infec-
tion-facilitating factor. Bioassay with PK resistant PrP gener-
ated from yeast cytoplasm and from the modiﬁed PMCA
reaction described here could potentially provide insight of
prion infection process.
Our results suggest that, at least, some of the cytoplasm gen-
erated PK resistant PrP conformation has the characteristic
prion property, the ability to self-propagate its PK-resistant
conformation. Although wild-type PrP is cell surface localized,
a portion of PrP enters the cytoplasm through either retro-
translocation from the ER [15] or impaired import into the
ER [16]. Normally, PrP in the cytoplasm is eﬃciently removed
by the proteasome [17]. However, if proteasome activity is
compromised, some PrP molecules might escape proteasome
degradation and gain the PrPSc conformation. Further studies
of cytoplasmic PrP will help us to elucidate whether it plays
any role in the pathogenesis of prion disease.
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